Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs Wix.Com Ltd — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while Wix.Com Ltd trades at $74 (market cap $3.00B). The key difference: Travere Therapeutics Inc. Common Stock is the larger of the two by market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Wix.Com Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and Wix.Com Ltd for 62 Days on average.
| TVTX | WIX | |
|---|---|---|
Market Cap | $4.88B | $3.00B |
Volume | 1,668,577 | 960,938 |
Sector | Health | Technology |
52-Week High | $67.52 | $145.54 |
52-Week Low | $26.79 | $40.43 |
Typical Hold Time | 0 Days | 62 Days |
Enterprise Value | $5.01B | $4.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
WIX trades at $74.31, up 0.18% on the day, with a bearish technical signal from moving averages but neutral oscillators. Revenue growth is strong, reaching $1.99B in 2025, though net income margin turned negative at -8.19% in 2026. The company faces multiple class-action lawsuits filed in September 2026, adding legal overhangs. Analyst consensus remains bullish with a $77.00 price target, but negative equity and volatile cash flows highlight financial instability.
The outlook is mixed: robust revenue growth and analyst support offer upside, but profitability challenges, negative equity, and legal risks pose significant headwinds. Investors should weigh the high P/E of 62.84 against earnings volatility and litigation uncertainties before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
